GlassScriptPhysician profile
John C Girod
NPI 1568546794
$763.47
in general payments reported to CMS, 2019-2025
15 companies · $17.27 in 2025
The $17.27 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $109 · 2021: $172 · 2022: $60.00 · 2023: $169 · 2024: $114 · 2025: $17.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $300.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $182.48 | 2019-2024 | Prolia, Evenity, Krystexxa |
| Abbvie INC. | $146.29 | 2020-2025 | |
| Gilead Sciences, INC. | $91.88 | 2019-2023 | |
| Tetraphase Pharmaceuticals, INC. | $76.02 | 2020 | |
| Allergan, INC. | $43.07 | 2019-2020 | |
| Smith+Nephew, INC. | $40.71 | 2022 | |
| Theratechnologies INC. | $32.03 | 2021 | |
| Astellas Pharma US INC | $29.24 | 2023 | Cresemba |
| Merck Sharp & Dohme LLC | $24.42 | 2019 | |
| Cvrx, INC. | $19.92 | 2023 | Barostim Neo System |
| Octapharma USA, INC. | $18.92 | 2023 | Panzyga |
| Pfizer INC. | $16.19 | 2024 | |
| Celgene Corporation | $15.29 | 2024 | Orencia |
| Teva Pharmaceuticals USA, INC. | $14.19 | 2021 | |
| Janssen Biotech, INC. | $12.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Girod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.